Avalilação PREreview de Clinical Impact of Ultra-Fast Whole Genome Sequencing in Paediatric Haematology-Oncology Practice
- Publicado
- DOI
- 10.5281/zenodo.20046566
- Licença
- CC0 1.0
“Clinical Impact of Ultra-Fast Whole Genome Sequencing in Paediatric Haematology-Oncology Practice”
Short summary of the research and contribution to the field
This preprint evaluates an Ultra-Fast Whole Genome Sequencing (UF-WGS) workflow for children with suspected or confirmed cancer in a tertiary pediatric hematology-oncology practice. The authors compare UF-WGS with the standard NHS Genomic Medicine Service WGS (GMS-WGS) workflow and report a major reduction in turnaround time: approximately 3 days from sample collection for UF-WGS versus 37 days for GMS-WGS. UF-WGS recalled 95% of clinically actionable somatic and germline variants identified by standard testing and detected 19 additional clinically actionable variants not found by GMS-WGS.
The work is important because pediatric oncology often requires rapid molecular diagnosis to guide risk stratification, treatment selection, trial enrollment, germline cancer predisposition assessment, and urgent clinical decision-making. The study moves the field forward by showing that ultra-fast WGS may not only be technically feasible, but also clinically meaningful in real-world pediatric hematology-oncology care. The reported impact on prospective cases is especially valuable because it begins to connect sequencing speed with patient-management decisions.
Positive feedback / strengths
Highly clinically relevant question. The study addresses a major limitation of routine cancer genomics: clinically useful genomic information often arrives too late to influence early management decisions.
Direct comparison with a real clinical benchmark. Using concurrent NHS GMS-WGS as the validation comparator strengthens the study because the authors are not comparing UF-WGS to an artificial or purely research-based standard.
Strong turnaround-time improvement. Reducing mean turnaround time from 37 days to 3 days is a major practical achievement and could substantially change clinical decision-making in pediatric oncology.
Focus on actionable somatic and germline findings. The study appropriately emphasizes clinically actionable variants rather than purely technical variant detection.
Prospective clinical-impact assessment. Reporting that UF-WGS improved care in 18/35 prospective cases adds important real-world relevance beyond analytical validation.
Useful attention to discrepant findings. The authors note that differences between workflows may relate to tumor heterogeneity and low variant allele frequency, which are realistic challenges in oncology sequencing.
Major issues
1. Clarify how “clinically actionable” was defined
The study’s main conclusions depend on the definition of clinically actionable somatic and germline variants. This term can vary widely depending on whether actionability includes diagnosis, prognosis, risk stratification, therapy selection, trial eligibility, germline predisposition, or change in surveillance.
Suggested improvement: The authors should provide a clear actionability framework, ideally including:
variant tiering criteria
somatic versus germline actionability categories
whether actionability was based on pediatric oncology guidelines, local molecular tumor board review, NHS criteria, or expert consensus
examples of management changes triggered by UF-WGS
whether variants of uncertain significance were excluded from the actionable category
This would make the clinical-impact claims easier to interpret.
2. Provide more detail on the UF-WGS analytical workflow
The abstract reports excellent turnaround time and high recall, but the manuscript should clearly describe the technical workflow that enabled this speed.
Suggested improvement: The authors should include details on:
sample input requirements
tumor-normal strategy
DNA extraction workflow
library preparation method
sequencing platform and run configuration
target coverage
bioinformatics pipeline
variant classes assessed: SNVs, indels, CNVs, structural variants, gene fusions, mutational signatures, and germline variants
minimum quality thresholds
reporting workflow and clinical review steps
A workflow figure showing sample collection → sequencing → analysis → clinical report would be very helpful.
3. The 19 additional actionable variants require deeper explanation and validation
UF-WGS identified 19 clinically actionable variants not detected by GMS-WGS. This is potentially important but needs careful interpretation.
Suggested improvement: For each additional actionable variant, the authors should summarize:
variant type
specimen type
tumor purity or disease burden
VAF or copy-number level
whether orthogonal confirmation was performed
whether the finding changed diagnosis, risk assignment, treatment, or germline counseling
why GMS-WGS did not detect or report it
Without this detail, readers may not know whether these were true additional clinically useful findings, pipeline/reporting differences, tumor heterogeneity effects, or low-level findings near detection thresholds.
4. Discrepant findings need a structured discordance analysis
The abstract states that discordances were attributable to tumor heterogeneity in some cases and low VAF in others. This is plausible, but the explanation should be evidence-based and case-specific.
Suggested improvement: The authors should provide a discordance table including:
variants detected by both methods
variants detected only by UF-WGS
variants detected only by GMS-WGS
sample source used for each workflow
sequencing depth and tumor purity
VAF / copy-number estimate
orthogonal confirmation status
final clinical interpretation
This would strengthen confidence in the comparative performance claims.
5. Clinical impact assessment should be described in more detail
The study reports that UF-WGS improved care in 18/35 prospective cases and that clinicians judged 9/19 retrospective cases would have benefited. These are strong claims, but the methodology needs detail.
Suggested improvement: The authors should clarify:
who adjudicated clinical impact
whether reviewers were independent or blinded
what counted as “demonstrable improvement in care”
whether changes included therapy change, diagnosis clarification, risk stratification, trial enrollment, transplant decision-making, germline counseling, or avoidance of additional testing
how disagreements between clinicians were resolved
whether patient outcomes were available
A structured clinical-impact rubric would make the findings more reproducible.
6. Cohort composition and generalizability need clearer presentation
The study includes 54 pediatric patients with suspected or confirmed cancer, but pediatric hematology-oncology is highly heterogeneous.
Suggested improvement: The authors should provide cohort breakdown by:
diagnosis group
suspected versus confirmed malignancy
diagnosis versus relapse
hematologic versus solid tumor
sample type
tumor cellularity / blast percentage
prospective versus retrospective cases
prior testing performed
urgency of clinical decision-making
This would help readers understand where UF-WGS is most useful and where performance may be less certain.
7. Germline findings raise consent, counseling, and reporting considerations
The study includes clinically actionable germline variants. In pediatric oncology, rapid germline reporting can have major implications for the child and family.
Suggested improvement: The authors should describe:
consent process for germline analysis
whether germline findings were confirmed in a validated germline workflow
genetic counseling process
whether parental samples were used
reporting policy for secondary or incidental findings
turnaround time for germline confirmation
This is important for real-world implementation.
8. Turnaround-time analysis should be broken down by workflow step
The reported 3-day mean TAT is a major finding. To help other laboratories evaluate feasibility, the authors should break down where time was saved.
Suggested improvement: Report TAT by:
sample receipt to extraction
extraction to library preparation
library preparation to sequencing
sequencing runtime
bioinformatics analysis
variant interpretation
clinical sign-out
This would make the workflow more actionable for other clinical genomic laboratories.
9. Cost, staffing, and implementation requirements should be discussed
Ultra-fast WGS may require specialized infrastructure, staffing, computational resources, and rapid clinical interpretation.
Suggested improvement: The authors should discuss:
sequencing cost per case
staffing model
need for after-hours or weekend workflows
computational requirements
molecular tumor board or rapid review process
whether the workflow is scalable outside a specialized tertiary center
comparison with targeted panels, RNA-seq, karyotyping, FISH, and rapid PCR-based testing
This would help readers assess implementation beyond the study center.
Minor issues
Define UF-WGS and GMS-WGS clearly at first use. A concise definition of both workflows would help readers outside the UK system.
Clarify “recall” terminology. The term “recalled 95%” should be clearly defined as sensitivity, positive percent agreement, variant-level recall, or case-level recall.
Provide confidence intervals. Recall rate, clinical-impact percentages, and TAT comparisons should include confidence intervals where possible.
Clarify whether the 3-day TAT is mean, median, or operational target. Median and range would be useful because ultra-fast workflows may have outliers.
Clarify whether all variant classes were equally assessed. SNVs, indels, CNVs, structural variants, fusions, mutational signatures, and germline variants may have different detection performance.
Include representative clinical cases. A small number of case vignettes would help show how UF-WGS changed real clinical decisions.
Discuss limitations of retrospective clinician judgment. Retrospective assessment of possible clinical benefit can be valuable but may be vulnerable to hindsight bias.
Explain “flowcell proximity data.” This phrase is interesting but unclear from the abstract. The manuscript should define it and explain how it may affect clinical care.
Clarify whether UF-WGS replaced or supplemented standard testing. Readers should understand whether UF-WGS is proposed as a first-line test, triage tool, or add-on workflow.
Discuss data-sharing and reproducibility. The authors should clarify whether pipeline details, workflow parameters, and anonymized benchmark data are available.
Overall assessment
This is a clinically important and potentially high-impact study showing that ultra-fast WGS can substantially reduce turnaround time and may improve care in pediatric hematology-oncology practice. The work is strong because it evaluates a real-world clinical workflow, uses concurrent standard GMS-WGS as a benchmark, and focuses on clinically actionable findings rather than purely technical sequencing performance.
The major improvements needed are clearer definitions of actionability and clinical impact, deeper analysis of discrepant variants, more transparent technical workflow details, and practical implementation information such as staffing, cost, scalability, and TAT breakdown. The study would also benefit from clearer discussion of germline reporting and consent, especially given the pediatric setting.
With these additions, the manuscript would provide a stronger and more actionable model for implementing rapid WGS in pediatric cancer care and could help guide broader adoption of ultra-fast genomic diagnostics in time-sensitive oncology settings.
Competing interests
The author declares that they have no competing interests.
Use of Artificial Intelligence (AI)
The author declares that they used generative AI to come up with new ideas for their review.